Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Arannilewa1, Abiodun Julius, Suleiman Alakanse, Oluwaseun, Adesola, Adesola Oluwaseun, Israel Malachi, Oluwaseyi, Michael Obaidu, Ifedayo, Oluwafemi, Emmanuel Ekun, Damilola Afolayan, Emmanuel, Folakemi Afere, Patricia, Abdullateef Ayuba, Kayode, Oluwafemi Bolarinwa, Tolulope, Oche Ambrose, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2018
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563659/
https://www.ncbi.nlm.nih.gov/pubmed/31223207
http://dx.doi.org/10.6026/97320630014482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563659/
https://www.ncbi.nlm.nih.gov/pubmed/31223207
http://dx.doi.org/10.6026/97320630014482

Ejemplares similares